•  
  •  
  •  
  •  

2026-07-22 02:06:22

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • CRISIL Limited Reports Q2 CY26 / Q1 FY27 Results: Consolidated Revenue Jumps 27.6% YoY to ₹1,075.39 Crore; Net Profit Reaches ₹216.46 Crore
  • Purple Finance Grants In-Principle Approval to Acquire 100% Stake in Saksham Gram Credit
  • InfoBeans Technologies Reports Q1 FY27 Results: Revenue Jumps 36.6% YoY to ₹152.77 Crore; Net Profit Stands at ₹21.62 Crore
  • Gamco Limited Reports Q1 FY27 Results: Consolidated Revenue Surges 105.8% YoY to ₹113.72 Crore; PAT Reaches ₹32.43 Crore
  • Gabriel India Reports Q1 FY27 Results: Consolidated Revenue Up 15.5% YoY to ₹1,425.68 Crore; Net Profit Reaches ₹108.13 Crore

Keywords Selected:  InjectableFacility

Stock Report

  • Alembic Pharmaceuticals Ltd receives 2 observations for Karakhadi Injectable Facility
  • Lupin receives EIR from US FDA for its Nagpur Injectable Facility
  • Zydus receives EIR for the injectable facility located at Jarod
  • Closure of USFDA inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad
  • Zydus receives EIR for the oncology injectable manufacturing facility in SEZ1, Ahmedabad
  • Lupin receives 6 observations from USFDA for Nagpur Injectable facility
  • Eris Lifesciences receives ANVISA approval for Sterile Injectable Facility
  • Lupin receives EIR from US FDA for its Injectable Facility in Nagpur
  • Eugia Steriles Pvt Ltd receives EIR from USFDA for new injectable facility
  • Eugia Steriles Pvt Ltd receives 1st production approval from USFDA from new injectable facility
  • Lupin announces closure of US FDA Inspection at its Injectable Facility with Zero 483 Observations
  • Eugia Steriles Pvt Ltd gets 3 observations from USFDA for Injectable Facility
  • Windlas Biotech Limited commissions its State-of-the-Art Injectable facility
  • Eugia US Manufacturing LLC gets 10 observations from USFDA for East Windsor facility
  • Lupin Receives EIR from US FDA for its Injectable Facility in Nagpur
  • Alembic Pharmaceuticals Ltd receives EIR from USFDA for Injectable Facility at Karkhadi
  • Lupin receives approval from US FDA for Glycopyrrolate Injection, USP
  • USFDA inspection at Alembic Pharmaceuticals Injectable Facility (F-3) at Karkhadi
  • Zydus Lifesciences Ltd gets 3 observations from USFDA for Injectable Facility

Latest Post

  • CRISIL Limited Reports Q2 CY26 / Q1 FY27 Results: Consolidated Revenue Jumps 27.6% YoY to ₹1,075.39 Crore; Net Profit Reaches ₹216.46 Crore
  • Purple Finance Grants In-Principle Approval to Acquire 100% Stake in Saksham Gram Credit
  • InfoBeans Technologies Reports Q1 FY27 Results: Revenue Jumps 36.6% YoY to ₹152.77 Crore; Net Profit Stands at ₹21.62 Crore
  • Gamco Limited Reports Q1 FY27 Results: Consolidated Revenue Surges 105.8% YoY to ₹113.72 Crore; PAT Reaches ₹32.43 Crore
  • Gabriel India Reports Q1 FY27 Results: Consolidated Revenue Up 15.5% YoY to ₹1,425.68 Crore; Net Profit Reaches ₹108.13 Crore


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025